Physician profile
Eric Chang
NPI 1477996031
$1,569.85
in general payments reported to CMS, 2019-2025
15 companies · $232 in 2025
The $232 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2021: $168 · 2022: $158 · 2023: $402 · 2024: $330 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $963.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $304.14 | 2021-2025 | Tavneos, Krystexxa |
| Janssen Pharmaceuticals, INC | $201.45 | 2024 | Xarelto |
| Calliditas Therapeutics US INC. | $132.48 | 2023 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $124.99 | 2023 | |
| Aurinia Pharma U.S., INC. | $123.97 | 2022 | |
| Fresenius USA Marketing, INC. | $111.12 | 2023 | Korsuva |
| Baxter Healthcare | $101.57 | 2019 | |
| Nxstage Medical, INC. | $91.73 | 2025 | Nxstage System One |
| Vifor Pharma, INC. | $89.38 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $88.77 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $68.43 | 2021 | |
| Daiichi Sankyo INC. | $54.12 | 2022-2023 | Injectafer |
| Collegium Pharmaceutical, INC. | $51.14 | 2025 | Belbuca |
| Novartis Pharmaceuticals Corporation | $13.69 | 2025 | |
| Glaxosmithkline, LLC. | $12.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.